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A Systematic Literature Review on the Capability of SiO₂-NP’s Exposure to Exacerbate
Parkinson’s (PD) Pathology and the Risk Factors for Biomedical Applications in PD.

ABSTRACT
Silica Dioxide nanoparticles (SiO₂-NP) have become increasingly ubiquitous in industry,
which has stimulated research into the potential toxicity of these compounds. Recent studies
have explored the association between amorphous silica nanoparticle exposure and the potential
for neurotoxicity. Additionally, research has been conducted in the application of SiO₂-NP’s in
theranostics and as drug directing agents , which based on current literature may be
contraindicated for individuals with conditions such as Parkinson's Disease (PD) which is
characterized by neuroinflammation. The following literature review will discuss evidence for
silica dioxide nanoparticle exposure to induce neurotoxicity which may exacerbate
neurodegenerative diseases such as PD. The following study selected articles based on the
criteria of known neurological pathologies seen in PD and utilized in-vitro neuronal cell
exposure assessment research to derive conclusions. SiO₂-NP dose-response in-vitro models
demonstrated significant damage to astrocytes, dopaminergic neurons, and upregulated
apoptosis. The systematic review provides insight into the general exposure risk to SiO₂-NP’s for
the PD population and proposes safety considerations for SiO₂-NP biomedical applications.

BACKGROUND
Silica Dioxide (SiO₂) is abundant in the earth’s crust and is present in a variety of
construction materials such as concrete, quartz, and brick. These materials are composed of what
are referred to as Silica Dioxide Nanoparticles, which in the event of human exposure can lead to
negative health outcomes. As reference for particle size, nanoparticles are particles between the
sizes 1 - 100 nanometres (10-9). SiO₂-NP’s exist in two forms: crystalline and amorphous, both
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structures have identical molecular formulas but differ in spatial arrangements of their atoms1
(Figure 1). The crystalline form has been well documented as a pulmonary toxicant leading to
respiratory health conditions such as silicosis, pulmonary fibrosis, and cancer. Amorphous silica
toxicity is less understood , yet the nanoparticles have become increasingly prevalent in
pharmaceuticals as nanocarriers for drugs intended to cross the blood brain barrier (BBB) in the
central nervous system (CNS).
Figure 1: Differing Spatial Arrangements of Crystalline versus Amorphous Silica. This is an
example figure illustration from Chowdhury, S. C., Haque, B. Z. (G., & Gillespie, J. W. (2016, July 27).
Journal of Materials Science https://link.springer.com/article/10.1007/s10853-016-0242-8

Various peer reviewed research has demonstrated that the primary mechanism of toxicity
for SiO₂-NP’s is macrophage mediated. The macrophage activation mediated mechanisms lead to
an alteration of function and cytotoxicity. Animal models and in-vitro neuron models have
shown SiO₂-NP’s to induce morphological and functional changes to glial and neuronal PC12
(Catecholamine dopaminergic cell models derived from pheochromocytoma of rat adrenal
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medulla), and astrocytes which constitute the BBB are extremely sensitive to SiO₂ exposure,
demonstrating formation of Lewy bodies made up of alpha-synuclein aggregates.
Alpha-Synucleinopathies are a common biomarker for the pathogenesis of
neurodegenerative diseases such as Parkinson’s Disease (PD). Multiple mechanisms of SiO₂
exposure are likely to exacerbate neuronal atrophy through damage to alpha-synuclein, inhibition
of ubiquitin proteasome system (UPS), activation of autophagy, and inevitably apoptosis.
Additionally , SiO₂-NP potential to damage mitochondria and the subsequent release of ROS
facilitates further degradation to proteins, lipids, and nucleic acids. The following literature
review will discuss evidence for silica dioxide nanoparticle exposure to induce neurotoxicity and
increase risk for neurodegenerative diseases such as PD. This will provide critical considerations
for the utilization and risk assessment of SiO₂-NP as nanocarriers for PD medications.

METHODS
Literature Search
The following literature review was conducted by searching peer reviewed journal
databases primarily utilizing the National Institute of Health National Library of Medicine
PubMed Database and ScienceDirect. Inclusion criteria for literature was based on two primary
characteristics such as articles discussing common neurological pathologies seen in PD and
articles discussing SiO₂-NP’s exposure impact on glial cells and dopaminergic neurons which are
pathologies relevant to PD. Search terms to gather foundational knowledge on parkinson
neurological pathology included “Parkinson’s Disease” and “Microglia'' which produced 2760
results and “Parkinson’s Disease” and “Astrocytes'' which produced 1800 results. Search results
which focused on the second characteristic such as SiO₂-NP’s capacity to induce neurotoxicity
relevant to PD included search results such as “Silica” and “neurons'' producing 163 results,
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“Silica” and “Astrocytes'' producing 23 search results, and “Silica” and “alpha synuclein”
producing 13 search results. Specific search results for inclusion criteria consisted of articles
containing key-words which connected PD and SiO₂-NP exposure such as “Parkinson’s Disease”
and “Silica Dioxide Nanoparticles.” This search query produced 11 results and produced
literature for the proposed utilization of SiO₂-NP’s as vehicles for parkinson’s treatment..
Articles were evaluated to determine if existing PD pathology may be exacerbated by
SiO₂-NP exposure based on SiO₂-NP neurotoxicity studies. Alpha Synuclein is a common
biomarker used to identify the presence of PD. The key word search for “Parkinson’s Disease”
and “Alpha-Synuclein '' produced 11,587 search results and articles were chosen based on
discussion of alpha-synuclein pathology and presentation in PD. In terms of SiO₂-NP exposure
“Silica Dioxide Nanoparticle” and “alpha-synuclein” produced 13 search results and inclusion
criteria was based on articles discussing SiO₂-NP exposure's impact on CNS glial cells and
neurons. Specific search terms were used to further locate references which discussed “L-Dopa”
and “Silica Dioxide Nanoparticles” which provided isolated results with 3 search results. Articles
were reviewed to analyze PD related silica dioxide nanoparticle neurotoxicity. This review was
performed as a risk assessment to determine the safety of using SiO₂-NP’s in biomedical drug
applications for PD patients. The review was based on two criteria categories SiO₂-NP exposure
risks and known PD pathologies such as alpha synuclein aggregation, astrocyte functional
changes, and neuroinflammation.
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Inclusion Criteria Diagram
Figure 2: Flowchart representing literature selection process hierarchy.

Exclusion Criteria for Literature Review
Articles were reviewed for specific discussion on elements of CNS neuroglial damage,
dopaminergic neurons damage, and inflammatory response to SiO₂-NP exposure relevant to PD.
Articles which discussed similar neurological diseases such as Alzheimers and dementia were
excluded. Articles were chosen based on the cell models which utilized in-vitro models and
animal models which evaluated exposure based on dose response. Articles which did not include
varying doses of exposure were excluded. Case series study designs were also excluded due to
low internal validity in these study designs.
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Table 1: Table of Contents for Relevant Information from articles. The table can be utilized if
the reader is interested in a particular topic related to Silica Dioxide Nanoparticle exposure and
neurotoxicity.

Section Number/Title

Topics

Key Points

1.0 Overview of Search
Results

- SiO₂-NP’s General Toxicity
- Astrocyte Sensitivity to
SiO₂-NP’s
- Neuron Sensitivity
SiO₂-NP’s
- Risk assessment for
SiO₂-NP’s in Parkinson’s
disease treatment

-Introduction of topics to be
addressed

2.0 Sources of SiO₂-NP’s

- Atomic Forms of SiO₂-NP’s
-Occupational Exposure
-Pharmaceutical and
Theranostic exposure

-Amorphous versus
Crystalline
-Common hazards in
construction sites
-Risk / benefit umbrella for
medical application of
SiO₂-NP’s

3.1 General Toxicity

-SiO₂ Macrophage Activation
-Sensitivity of Neurons to
SiO₂
-Environmental exposure
studies
-SiO₂ Susceptibility in
populations with pulmonary
disease

-SiO₂ evasion of
macrophage particle clearing
mechanisms
-Release of proinflammatory
mediators
-SiO₂ nanoparticle
exacerbation of existing
inflammatory disease

3.2 Astrocyte Sensitivity to
SiO₂-NP’s

-Astrocyte function
-Astrocyte alteration
following SiO₂ exposure

-SiO₂-NP’s exposure and
impact on glial cell function
-Morphological changes as a
result of SiO₂-NP exposure
-Implications to BBB barrier
and BBB pathology in PD.

4.1 Alpha-Synuclein
Aggregation

-PD an alpha-synucleinopathy -Alpha-Synuclein a
-Lewy Bodies
pathology seen in those with
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-SiO₂-NP increases
expression of alpha-synuclein

PD
-Alpha-Synuclein Aggregate
formation of Lewy Bodies
-PC12 cell model provides a
mechanism for SiO₂-NP
exposure and loss of
dopaminergic neurons.

4.2 PC12 Potential
Mechanisms of toxicity

-Ubiquitin Proteasome
System
-Autophagy
-Dopaminergic Neuron Cell
Models (PC12)
-ROS
-Microglial activation

-Insoluble Lewy bodies of
alpha-synuclein
accumulation and resist
degradation.
-Cellular dysfunction and
programmed cell death
-Silica Dioxide Nanoparticle
exposure causes
proinflammatory response in
CNS which releases ROS.
-The oxidative stress from
ROS damages proteins,
astrocytes, mitochondria,
and degradation pathways.

4.3 Alpha-synuclein
Misfolding

-Alpha-Synuclein change
from alpha-helical shape to
beta pleated shape

-Beta pleated shape is
resistant to degradation by
UPS.
-The misfolding of alpha
synuclein is a common
pathology of PD, and the
ROS from SiO₂-NP
exposure inhibits
degradation of these proteins
by a variety of mechanisms.

4.4 SiO₂-NP considerations
for L-Dopa Delivery

-L-Dopa amino acid
precursor used in PD
treatment
- SiO₂-NP as drug directing
agents

-Levodopa efficacy
gradually decreases in
treatment of PD
- SiO₂-NP considered for
usage as a method to
gradually release L-Dopa
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RESULTS
1.0 Overview of Search Results
The selected articles discuss the potential for SiO₂-NP’s to induce neurotoxicity by
alteration of cell function by inducing morphological changes to glial cells, increased expression
of alpha-synuclein Lewy bodies in neurons and dopaminergic cell death. One study in particular
used a Lipopolysaccharide (LPS) model to demonstrate the impact of SiO₂-NP’s environmental
dust to lung pathologies in individuals with inflammatory lung diseases, which provides a basis
for SiO₂-NP to exacerbate existing inflammatory disease. Other studies focused on SiO₂-NP’s
capacity to cross the BBB and have been studied for their use as a drug directing agent for
L-Dopa. The systematic summary and evaluation of the below compilation of research exhibits a
cause for concern for using SiO₂-NP’s in the treatment for PD. Ultimately, these particles may
contribute to the progression of PD disease pathology. Each heading represents published
research discussing the evidence of potential toxicity of SiO₂-NP’s specifically in individuals
with PD.
2.0 Sources of Silica Dioxide
SiO₂ nanoparticles (SiO₂-NP) are natural compounds which exist in two varieties:
crystalline and amorphous. Although both forms are molecularly identical , the two types consist
of different atomic arrangements. Crystalline silica arrangements have repeating patterns and
amorphous silica atoms exist in random linkages.¹ Exposure to these particles occurs in both
occupational and non-occupational settings due to their widespread use. Occupationally,
construction materials such as concrete, mortar, stone, brick, and ceramics are abundant in
crystalline silica. The amorphous form of silica is often found in food additives, cosmetics, and
in medical applications.²
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Mitigation strategies are routinely implemented in construction sites due to the well
documented evidence of crystalline silica to cause pulmonary disease such as silicosis. The
primary site of host entry is through the inhalation route where the particles can then interact
with endogenous molecules. A dose-dependent association exists between exposure and
accumulation and the biological fate of these particles are pertinent to SiO₂-NP potential to
cause toxicity. Pharmaceutical and theranostic exposure to SiO₂ is another source of host entry as
amorphous/mesoporous silica is utilized as nanocarriers to transport medications across the BBB
of the CNS.³ The usage of amorphous silica in medical applications is typically carried out under
a risk/benefit umbrella but recent research using animal cell models have indicated potential for
toxicity.
3.1 General Toxicity
Silica nanoparticles are generally classified as an inhalable toxicants which interact with
immunocompetent cells to induce immunotoxicity.⁴ The physicochemical properties of
SiO₂-NP’s , specifically their size, contribute to toxicity and cell interaction. Proinflammatory
mechanisms are the general catalyst for toxicity which initiates a cascade that leads to oxidative
stress, autophagy, and morphological changes to cell phenotypes.
The proinflammatory responses are the key in evaluating SiO₂-NP’s induced
immunotoxicity. The immune cells such as macrophages are the first responders to host exposure
to SiO₂-NP’s..⁴ Macrophages are phagocytes which will engulf harmful particles to protect cells
from damage. The biological fate of SiO₂ upon entry to the host is within a resident macrophage ,
in the lungs the alveolar macrophage interacts with the nanoparticles which are inhaled. The
small size of nanoparticles allow these molecules to escape particle-clearing defensive
mechanisms, causing proinflammatory responses which release cytokines, chemokines, and
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interferons. Macrophages exist in two phenotypes M1 being proinflammatory and M2 being anti
inflammatory, the M1 macrophages readily phagocytize SiO₂ nanoparticles while M2 take up
fewer particles..⁴ Inflammatory responses can influence cell functions negatively through
oxidative stress by producing ROS and by changing cell behavior. Furthermore, the damage is
compounded if inflammation is present prior to exposure to SiO₂-NP’s as seen in research that
utilized endotoxin in lung disease models.
A study by ( Ko, JW et al 2018) analyzed the environmental exposure of silica dioxide
common in areas between China and Mongolia from dust storms termed “Asian dust” which is
common in east asian countries. The greatest component of this dust was SiO₂ with a
concentration of 52.3%.⁵ Inevitably, this resulted in chronic exposure for residents of these
geographic areas as this dust is inhaled in daily life. To investigate potential toxicity of respirable
SiO₂-NP’s researchers used a pulmonary disease model which utilized the endotoxin
lipopolysaccharide (LPS). Lipopolysaccharide is a major component of the outer membrane of
gram negative bacteria, LPS exposure causes respiratory inflammation and lung function decline
which can ”mimic '' pre-existing lung diseases. The model used mice which received LPS
induced lung injury followed by intranasal instillation of silica dioxide. Additionally, control
group mice received LPS only, the exposure to SiO₂ increased airway inflammation and the
production of proinflammatory cytokines. The results showed that those that received SiO₂
particles along with LPS exhibited an increased inflammatory response when compared to LPS
alone. This indicates support to prior studies which have shown that chronic SiO₂-NP exposure
can damage lungs through inflammatory mediated pathways and is accelerated in those with
pre-existing pulmonary morbidities.. ⁵
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Damage is not only localized to alveolar macrophages, as changes to tissue resident
macrophages are seen in other areas such as the nervous system. Microglial cells are the
macrophages of the brain and spinal cord and provide defense for the central nervous system
(CNS).⁴ SiO₂-NP’s are engulfed by microglia and accumulate in the endoplasmic reticulum and
lysosomes. Low levels of SiO₂ are able to alter the function of microglial cells and thus release
proinflammatory mediators. The proinflammatory mechanisms initiated by SiO₂-NP’s can cause
cell dysfunction and cytotoxicity.⁴ This is particularly dangerous in the CNS as neurons are
unable to undergo mitotic division which means any cell death whether through apoptosis or
necrosis is permanent. The results of the LPS study can be applied to the capacity of SiO₂-NP’s
to increase neurotoxicity in populations already vulnerable, such as those with Parkinsons,
Alzeimers, or dementia. Individuals with PD have a pathology characterized by
neuroinflammation and compromised BBB barrier. SiO₂-NP’s exposure can exacerbate the
pre-existing inflammation if the particles cross the BBB.
3.2 Astrocyte sensitivity to SiO₂-NP’s
Astrocyte sensitivity to SiO₂-NP’s indicates a risk factor for neurodegenerative diseases
such as Parkinson’s disease which is characterized by a compromised BBB. Astrocytes are
regarded as CNS glial cells which play a vital role in the constitution of the BBB. Their duty
includes the regulation of blood flow, transfer of mitochondria, and supplying the building
blocks for neurotransmitters.6 In-Vitro models using astrocyte rich cultures determined a
dose-dependent relationship between SiO₂-NP’s exposure and morphological changes to
astrocytes. Astrocytes exposed to 1, 10, and 25 µg/mL SiO 2-NPs showed subtle morphological
differences compared to control, where as astrocytes treated with 50 and 100 µg/mL showed
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substantial morphological changes to astrocytes with marked decrease in size of the cell’s soma
and development of thin scarce ramifications.7
The pathogenesis of PD consists of a compromised BBB and this disruption has been
noted in animal models for PD. The BBB disruption was further analyzed in 49 PD patients
using MRI which found subtle disruptions in BBB integrity. The BBB disruption is attributed to
changes in tight junctions, and damage from proinflammatory cytokines which can alter vascular
endothelial growth factor (VEGF).⁸ The pathogenesis of PD is characterized by a compromised
BBB consisting of leaky capillaries. The capillaries of the BBB normally consist of continuous
capillaries with tight junctions promoting reduced permeability. Leaky capillaries comprise the
selective permeability of the membrane making the CNS susceptible to toxic substances which
can enter the brain through passive diffusion. Certain reports indicate nanoparticles to have a
significant impact on BBB integrity. For example exposure to silver nanoparticles have shown
permeability of the BBB to increase in an in-vitro model. A similar mechanism may be plausible
due to silica nanoparticles interaction with astrocytes triggering changes to angiogenesis via
VEGF. VEGF is increased in brain tissue surrounding cerebrovascular trauma and leads to
increased BBB permeability.⁹
4.1 Alpha-Synuclein Aggregation
Parkinson’s disease pathology is the result of the progressive deterioration and loss of
dopaminergic neurons in the substantia nigra.10 The formation of Lewy bodies consisting of
alpha-synuclein aggregates are biomarkers for neurodegenerative diseases such as Parkinson’s.
Lewy bodies are clumps of protein which build up within neurons altering cell function. This
pathology of PD classifies the disease as an alpha-synucleinopathy. PC12 (catecholamine cells
derived from rat models) demonstrate significant alpha-synuclein aggregation and the presence
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of Lewy Bodies in response to silica nanoparticle exposure. Multiple studies have found
evidence that alpha-synuclein degradation is mediated by changes in ubiquitin-proteasome
system (UPS) and in autophagy.10
PC12 are animal cell models that represent catecholamine releasing cell types,
particularly dopaminergic neurotransmitters.10 Alpha synuclein is a protein involved in
neurotransmitter release, and inhibits neurotransmitter release when overexpressed..11 The
aggregation of insoluble protein clumps of alpha-synuclein can lead to cytotoxicity and
apoptosis. The data suggested that SiO₂-NP’s induced oxidative stress in form of ROS which led
to alpha-synuclein aggregation through the inhibition of ubiquitin-proteasome and activation of
autophagy..10 In PC12 cells which were exposed to silica nanoparticles alpha-synuclein
expression was upregulated in a dose dependent manner over a 24 hour period in vitro. The
accumulation of these proteins promote Lewy bodies (clumps of protein) which are often
considered a hallmark pathology of PD.10
4.2 PC12 Cells Potential Mechanisms of Toxicity
The likely culprit of oxidative stress results from microglial mediated proinflammatory
response to silica dioxide nanoparticle exposure. Damage to cellular mitochondria releases ROS
which is the source of oxidative stress, ROS can damage and induce alpha-synuclein aggregation
through inhibition of ubiquitin..11 Astrocytes also contribute to the proinflammatory cascade
which results in dopaminergic cell damage. When immune responses are activated by microglial,
astrocytes will surround the area to prevent the proliferation of toxic signals to surrounding
healthy tissues. Astrocytes play essential roles in maintaining neuronal health by providing
structural and metabolic support including transfer of mitochondria.12 In-vitro models have
shown sensitivity of astrocytes to SiO₂-NP’s and their role in surrounding activated microglial.
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This may be a plausible mechanism for the damage to neuronal mitochondria and the subsequent
increase of oxidative stress in the form of ROS. Figure 3 provides a schematic of the proposed
mechanism which results in apoptosis of dopaminergic neurons.
Figure 3: General flowchart of characteristics exacerbating alpha-synuclein aggregation, figure from Xie,
H., & Wu, J. (2016, September 6). Silica nanoparticles induce alpha-synuclein induction and aggregation in PC12-cells. Chemico-Biological
Interactions. Retrieved July 9, 2022, from https://www.sciencedirect.com/science/article/abs/pii/S0009279716303672 10

4.3 The Misfolding of Alpha-synuclein
Alpha-synuclein aggregation is initiated by damage which leads to a misfolding of the
protein from an alpha-helical shape to beta pleated sheets.13 A property of the misfolded
alpha-synuclein aggregates is that the protein clumps are unable to be degraded resulting in
cytotoxicity through apoptosis. The ubiquitin-proteasome system’s function is to degrade
intracellular soluble proteins.14 However, the oxidative stress following silica nanoparticle
exposure has been shown to inhibit ubiquitin allowing protein clumps of alpha-synuclein to
accumulate. Autophagy which is a lysosomal mediated degradation and clean up of cell materials
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is upregulated following exposure. Excessive Autophagy can be detrimental and lead to
apoptosis referred to as programmed cell death. Ultimately, the mechanisms of cytotoxicity can
result in cell death through autophagy. Autophagy is considered a protective mechanism to
degrade cellular components which are altering cell functions. Autophagy is conducted through a
lysosomal pathway, when a vacuole fused with a lysosome forms within the cell and digests
cellular components such as proteins back into smaller building blocks such as amino acids,
sugars, and lipids. If cellular deprivation is severe and autophagy excessive, cells will die from
autophagy.15
4.4 SiO₂-NP Considerations for L-Dopa Delivery
SiO₂-NP’s have been considered and studied in-vitro as drug directing agents in an oral
administration of L-Dopa to combat issues with gradual decreasing efficacy of Levodopa.
L-Dopa is an amino acid precursor to dopamine and its usage helps manage PD symptoms
related to loss of dopaminergic neurons.18

DISCUSSION
Silica Dioxide nanoparticles are able to disrupt many intracellular mechanisms by
inducing proinflammatory mechanisms. The cytokines, chemokines, and interferons are not
precisely selective in where inflammation is induced following the phagocytosis of SiO₂-NP’s.
Microglial sensitivity to silica can become a major contributor to neuroinflammation which
places populations with neurodegenerative disease at further risk. Glial cells such as astrocytes
and dopaminergic neurons are particularly vulnerable to silica exposure and demonstrate
morphological and functional changes. Oxidative stress in astrocytes can damage the BBB ,
proteins and mitochondria in the CNS. The damage to mitochondria in particular may be the key
source of ROS which induces alpha-synuclein Lewy bodies, the inhibition of ubiquitin, and the
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activation of autophagy. The studies referenced depict a clear relationship between exposure to
silica dioxide and the interference of degradation pathways such as ubiquitin proteasome system
(UPS) and autophagy.
Astrocytes are the most abundant glial cell type in the CNS encompassing 20-40% of
total glial cells. Astrocytes serve critical roles in supporting neurons and in regulating CNS
function. Sensitivity of astrocytes to SiO₂-NP’s constitutes a significant risk for PD pathology
due to their diverse function. Astrocytes have end feet processes which attach to capillaries and
to neuronal synapses. These structural features are critical for astrocytes ability to maintain BBB
by regulating neurovascular blood flow. Astrocytes as gatekeepers use their terminal end feet
processes to regulate entry of metabolites such as glucose and lactate. As seen in the reviewed
literature astrocytes can secrete VEGF increasing angiogenesis and therefore permeability, this is
upregulated in response to neuroinflammation. This upregulation may be due to a variety of
reasons , such as allowing more macrophages into the CNS to mount an immune response.
Another important role of astrocytes is their interaction with neuronal synapses by re-uptaking
glutamate, an excitatory neurotransmitter. It has been proven that glutamate receptor dysfunction
is a factor in the altered neurotransmission in PD. Glutamate has become an area of new research
as a target for improved therapeutic intervention in PD.16 SiO₂-NP exposure demonstrated dose
dependent morphological changes to astrocytes which included decrease in cell soma size and
poorly developed end-feet projections. The article referred to these projections as “ramifications”
where research observed scarce and thin astrocyte end-feet. The susceptibility of astrocytes
SiO₂-NP’s creates an added risk factor for exposure in individuals with PD. Morphological
dysfunction to astrocytes inhibits the glial cell’s ability to support neurons by sourcing
metabolites such as glucose or by re-uptaking glutamate, an excitatory neurotransmitter.
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Reviewed studies such as the Role of Astrocytes in Parkinson’s Dysfunction demonstrate the
pathological changes seen in astrocytes for those with PD. The usage of SiO₂-NP in medical
applications poses an increased risk for further damage to astrocytes for those with PD and
should be strongly considered before being utilized in treatment for the PD population.
The usage of SiO₂-NP’s in biomedical applications depends significantly on the dose and
duration of treatment. There is a scarce amount of long-term toxicological data on the usage of
SiO₂-NP’s in treatments and theranostics. Mesoporous silica nanoparticles have already been
implemented as theranostic agents and as antitumoral nanomedicines.17 There has also been
research conducted on the utilization of SiO₂-NP’s as drug directing agents for levodopa, a drug
consisting of amino acid derivatives used to treat PD. Dose-dependent relationships are
important considerations in theranostics and cancer treatment; the benefits likely outweigh the
risks to the short-term and acute exposure to these treatments. In regards to chemotherapy drugs
SiO₂-NP’s are able to deliver drugs to diseased tissues by a selective / controlled method.17
Overall, the toxicity of chemotherapeutic drugs themselves are more highly toxic than the
SiO₂-NP’s that are used as the vehicle of delivery.
Applications SiO₂-NP’s as vehicles for delivery of levodopa have entirely different risks
due to the chronic and long-term usage of these medications. Levodopa (L-dopa) is an amino
acid used for the long-term treatment of PD as L-dopa is an immediate precursor to dopamine.18
SiO₂-NP’s as vehicles for L-dopa are likely considered for their strong capacity to cross the BBB
barrier , however research has shown that these SiO₂-NP’s can contribute to the pathologies of
PD through promotion of neuroinflammation and alpha-synuclein aggregation. SiO₂-NP’s in the
treatment of PD should be carefully considered and further studied as long-term use of these
particles in pharmaceuticals may impact the disease negatively.
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Certain studies have briefly discussed methods to mitigate damage caused by SiO₂-NP’s
such as the use of n-acetyl-cysteine in-vitro. According to one of the studies reviewed,
n-acetyl-cysteine did reduce the expression of alpha-synuclein in PC12 cells.10 It is critical, to
consider that although this seemed to have beneficial results in-vitro, it would not necessarily
translate into effective treatment in-vivo, as BBB barrier and first pass metabolism should also be
considered. n-acetyl cysteine is a reactive precursor for glutathione, a biotransformation enzyme
that acts as one of the body's most widely used antioxidants. Oral administration of n-acetyl
cysteine would likely result in biotransformation in the liver in first pass metabolism to
glutathione, leaving limited n-acetyl-cysteine to cross the BBB. At this time the best mitigation is
to prevent excessive exposure to SiO₂-NP’s particularly through the inhalation route and by
limiting exposure to long term SiO₂-NP’s treatment modalities.
Excretion and Limitations
Figure 4: Visual representation of oral administration of silica dioxide. Figure from:

Lee, J.-A., Kim,
M.-K., Paek, H.-J., Kim, Y.-R., Kim, M.-K., Lee, J.-K., Jeong, J., & Choi, S.-J. (2014, December 15). Tissue distribution and
excretion kinetics of orally administered silica nanoparticles in rats. International journal of nanomedicine. Retrieved October
18, 2022, from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279759/#:~:text=Elimination%20profiles%20showed%207%25–8,of%20partic
le%20size%20or%20sex.

The biodistribution and excretion of SiO₂-NP’s are important factors in the toxicity of
nanoparticles. A study by (Lee, J et al 2014) investigated tissue distribution and excretion
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kinetics of orally administered SiO₂-NP’s in rats. Excretion kinetics analyzed two sizes of
SiO₂-NP’s 20nm and 100 nm with doses varying between 500-1000 mg/kg. The primary location
of tissue distribution of particles were in the liver, kidney, and spleen. Figure 4 shows imaging
results from the excretion kinetics study with each column representing the different sizes of the
nanoparticles. These findings were consistent for all doses and particle sizes administered.
Interestingly, it was determined that silica nanoparticles had low accumulation in the brains of
SiO₂-NP treated rats. Excretion kinetics were measured by evaluating SiO₂-NP levels in urine
and feces post-administration. The study estimated that 7-8% of particles were removed via urine
and 75-80% of particles were removed through feces.19 Surprisingly, the smaller 20 nm particles
were shown to be eliminated more rapidly than the larger 100 nm particles.
There are several limitations and gaps in research based on biodistribution and excretion
kinetics research. The majority of this information contradicts the toxicity shown from the
in-vitro cell model research on astrocyte and PC12 exposure to SiO₂-NP’s. The cell model
research designs were conducted in culture and may not accurately represent what happens
in-vivo. In the in-vitro studies the neurotoxicity is readily seen as the particles had less barriers to
CNS entry. In-vivo following exposure the nanoparticles would have to absorb into systemic
circulation and cross the BBB. As reviewed previously, PD patients have BBB barrier
dysfunction consisting of an altered structure of capillaries which are significantly more “leaky”
than the tight junctions expected in a healthy individual. The excretion kinetics evaluated orally
administered Silica Dioxide Nanoparticles primarily determining the biodistribution of
gastrointestinal absorption of Silica Dioxide Nanoparticles. If SiO₂-NP based drugs were used
the target organ would be the brain, which means the drugs would need to be synthesized by a
method which promotes entry into systemic circulation. Oral administration exhibited increased
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levels of SiO₂-NP’s in the liver, kidney, intestines, and spleen and due to mechanisms such as
first-pass metabolism and intestinal absorption it allows the particles to pass merely unchanged
in feces. In the PD population the risk of the particles entering the CNS is more likely due to
BBB /astrocyte dysfunction and due to neuroinflammation allowing leaky capillaries for
monocyte infiltration. The route of exposure is the most relevant consideration for example it is
well understood that inhaled SiO₂-NP’s are able to evade macrophage particle clearing
mechanisms.
Furthermore the excretion study mentioned how the particles were excreted and
distributed but not the percent elimination. Many toxic exposures result in biomarkers of
exposure that can be measured in urine /feces, the important question is if any particles remain
and if they were excreted before altering target organ functions. This research model also
investigated a single time exposure which provided information on acute toxicity but not on the
outcomes of chronic exposure.
Pubic Health Solutions
The most compelling public health application will be to determine an exclusion criteria
which identifies vulnerable populations before recommending medical modalities which utilize
SiO₂-NP’s. Dose and duration of exposure are the most pertinent factors which would be
classified by frequency/magnitude of exposure. Important considerations are whether SiO₂-NP’s
will be utilized as a one time exposure theranostically or as part of a long term treatment plan.
The exposure route of SiO₂ is also a relevant consideration before determining a medical
application. For example whether the SiO₂-NP’s are orally administered or intravenously
administered. The target organs of these particles are of critical importance, such as if the
particles are intended to cross the BBB and it can be inferred that this is the goal if silica
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particles are being utilized as drug directing agents to the CNS. Orally administered silica
dioxide nanoparticles excretion kinetics demonstrate that exposure from the oral route exhibits
no signs of acute toxicity at doses up to 1000 mg/kg. Ultimately, it is unlikely that oral
administration of SiO2 particles or particles in food supply would result in adverse outcomes.
Lack of awareness is another driving risk factor as silica exists in many materials and
exposure is prevalent in the occupational settings particularly in construction. Many sites for
example implement mitigation efforts in occupational sites such as applying concrete “wet”
which prevents the nanoparticles from becoming respirable. Public health professionals should
remain increasingly vigilant as SiO₂-NP’s exposure becomes ubiquitous and as new applications
are continually considered. At the moment preventing environmental exposure to respirable
silica still remains the most pertinent area for education, especially within vulnerable
populations.

Conclusion
Increasing evidence is demonstrating SiO₂-NP’s can catalyze damage to the CNS
especially in those with neuroinflammatory conditions. Recent applications of SiO₂-NP’s in
biomedical applications have stimulated further research in the field to determine risk of
exposure from these routes. Current literature has suggested that SiO₂-NP’s have the capacity to
induce toxicity in-vitro to multiple body systems by a similar proinflammatory mechanism seen
in the respiratory system. The sensitivity of glial cells and dopaminergic cells to SiO₂-NP’s of the
CNS are critical considerations as widespread use of nanoparticles in biomedical applications
continues to rise. When considering the risk of these agents dose, duration, and route of exposure
should be the main considerations before implementing SiO₂-NP’s in medical treatment. Many
inherent risks exist in nanoparticle drug applications based on the inflammatory pathologies of
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PD and the known potential for neurotoxicity. Furthermore , SiO₂-NP based drugs for PD must
be taken daily by most individuals with PD increasing the risk of dose-dependent toxicity. The
vast majority of excretion kinetic research focuses on acute single exposures to SiO₂-NP’s.
Currently, there is not enough long-term toxicological data on the usage of SiO₂-NP’s for the
treatment of PD.
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Professional Competencies Fulfilled in Capstone Project
The foundational competencies included in this Capstone project are within the evidence based
approaches to public health category. Particularly, MPHF2 and MPHF4 are met in this project.
MPHF2 is the usage of quantitative and qualitative data collection methods for public health
context. MPHF4 is a competency which involves interpreting results of data analysis for public
health research. These two concentration competencies are included throughout this systematic
literature review.
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MPH Core Competencies Fulfilled In Capstone Project

Core competencies applied were EOHMPH2 and EOHMPH5. EOHMPH2 examines exposure
pathways of environmental and occupational health agents. The second competency EOHMPH5
involves the dose-response principle to assess exposure risk; this competency is discussed
thoroughly as SiO2-NP’s demonstrate toxicity in a dose-dependent manner.
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